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nsulin-like growth factor (IGF)-1 plays crucial roles in
growth control and rearrangements of the cytoskeleton.
 
IGF-1 binds to the IGF-1 receptor and thereby induces
the autophosphorylation of this receptor at its tyrosine
residues. The phosphorylation of the IGF-1 receptor is
thought to initiate a cascade of events. Although various
signaling molecules have been identiﬁed, they appear to
interact with the tyrosine-phosphorylated IGF-1 receptor.
Here, we identiﬁed leukemia-associated Rho guanine
nucleotide exchange factor (GEF) (LARG), which contains
 
the PSD-95/Dlg/ZO-1 (PDZ), regulator of G protein signaling
(RGS), Dbl homology, and pleckstrin homology domains,
as a nonphosphorylated IGF-1 receptor-interacting molecule.
LARG formed a complex with the IGF-1 receptor in vivo
 
,
I
 
and the PDZ domain of LARG interacted directly with the
COOH-terminal domain of IGF-1 receptor in vitro. LARG
had an exchange activity for Rho in vitro and induced the
formation of stress ﬁbers in NIH 3T3 ﬁbroblasts. When
MDCKII epithelial cells were treated with IGF-1, Rho and
its effector Rho-associated kinase (Rho-kinase) were activated
and actin stress ﬁbers were enhanced. Furthermore, the
IGF-1–induced Rho-kinase activation and the enhancement
of stress ﬁbers were inhibited by ectopic expression of the
PDZ and RGS domains of LARG. Taken together, these
results indicate that IGF-1 activates the Rho/Rho-kinase
pathway via a LARG/IGF-1 receptor complex and thereby
regulates cytoskeletal rearrangements.
 
Introduction
 
Insulin-like growth factor (IGF)*-1 is a polypeptide hormone
that is similar to insulin and plays fundamental roles in
mammalian growth processes. Binding of IGF-1 to the ex-
tracellular 
 
 
 
-subunit of the IGF-1 receptor results in the
autophosphorylation of the cytoplasmic 
 
 
 
-subunit of the
receptor (White and Kahn, 1994). The autophosphoryla-
tion of the IGF-1 receptor leads to the activation of various
IGF-1–dependent signal transductions (Myers and White,
1996). IGF-1 also plays crucial roles in rearrangements of
the cytoskeleton such as those which occur in membrane
ruffling (Kim et al., 1998), cell migration (Mañes et al.,
1999), and neurite outgrowth (Kim et al., 1997). However,
it remains to be clarified how IGF-1 affects such rearrange-
ments. In this study, we identified a cDNA encoding a
PSD-95/Dlg/ZO-1 (PDZ) domain as an IGF-1 receptor-
interacting molecule. This PDZ domain was almost identical
to the PDZ domain of leukemia-associated Rho guanine
nucleotide exchange factor (GEF) (LARG) (Kourlas et al.,
2000).
The Rho family GTPases play roles in cytoskeletal rear-
rangements and in cell adhesion in response to extracellular
signals. Rho participates in regulation of various cellular
functions such as stress fiber and focal adhesion formation
(Ridley and Hall, 1992, 1994), smooth muscle contraction
(Hirata et al., 1992; Gong et al., 1996), and membrane ruf-
fling (Nishiyama et al., 1994; Takaishi et al., 1995). Rho has
GDP-bound inactive and GTP-bound active forms, which
are interconvertible by GDP/GTP exchange and GTPase re-
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actions (Nobes and Hall, 1994). The GTPase reaction is
regulated by Rho GTPase-activating proteins. The GDP/
GTP exchange reaction is regulated by various GEFs and
by inhibitory proteins such as Rho GDI (Fukumoto et
al., 1990). GTP-bound Rho exerts its biological functions
through interaction with specific effectors (Van Aelst and
D’Souza-Schorey, 1997; Hall, 1998; Kaibuchi et al., 1999).
GEFs for the Rho family GTPases share a common se-
quence motif designated as the Dbl homology (DH) do-
main (Cerione and Zheng, 1996; Whitehead et al., 1997;
Stam and Collard, 1999). In addition to the DH domain,
GEFs for the Rho family GTPases contain a nearby pleck-
strin homology (PH) domain. Both domains are essential for
the GEF activity. Although several GEFs have been identi-
fied, the molecular mechanisms by which the activation of
GEFs is modulated by extracellular signals are largely un-
known except in the case of p115 RhoGEF, PDZ-RhoGEF,
and Vav. Studies on heterotrimeric G proteins have clarified
the mechanism by which p115 RhoGEF is regulated. p115
RhoGEF has the regulator of G protein signaling (RGS) do-
main, and the RGS domain of p115 RhoGEF specifically
stimulates the intrinsic GTPase activity of G
 
 
 
12
 
 or G
 
 
 
13
 
(Hart et al., 1998; Kozasa et al., 1998). Activated G
 
 
 
13
 
 con-
versely binds to p115 RhoGEF and stimulates its ability to
catalyze nucleotide exchange of Rho. Thus, upon stimula-
tion by extracellular signals the activation of G
 
 
 
13
 
 is thought
to be linked to the activation of Rho via p115 RhoGEF.
Similarly, it has been reported that the RGS domain of
PDZ-RhoGEF (KIAA0380) interacts with activated G
 
 
 
12
 
 or
G
 
 
 
13
 
 (Fukuhara et al., 1999). Vav and Vav-2 are other
GEFs for the Rho family GTPases (Crespo et al., 1997;
Schuebel et al., 1998; Abe et al., 2000). The phosphoryla-
tion of Vav and Vav-2 on tyrosine residues leads to the acti-
vation of the Rho family GTPases (Crespo et al., 1997;
Schuebel et al., 1998). Recently, it has been reported that
Vav-2 participates in the hepatocyte growth factor (HGF)–
stimulated activation of Rho (Kodama et al., 2000).
It has been suggested that the Rho family GTPases partic-
ipate in the IGF-1 signaling pathway (Thomson et al., 1997;
Cheng et al., 2000); however, the mechanism of regulation
of the Rho family GTPases by IGF-1 is unknown. In this
study, we found that the IGF-1 receptor formed a complex
with LARG and that IGF-1 induced the activation of Rho
and its effector Rho-associated kinase (Rho-kinase)/ROK/
ROCK (Leung et al., 1995; Ishizaki et al., 1996; Matsui et
al., 1996) in MDCKII epithelial cells. The IGF-1–induced
activation of Rho-kinase was inhibited by pretreatment of
the cells with Rho-kinase inhibitors and by overexpression of
the PDZ and RGS domains of LARG.
 
Results
 
Identification of LARG as an IGF-1 
receptor-interacting molecule
 
To clarify the mechanism underlying the IGF-1/IGF-1 re-
ceptor signaling pathway, we tried to identify IGF-1 recep-
tor-interacting molecules by the yeast two-hybrid screening
method. We used the COOH-terminal 20 amino acids of
the IGF-1 receptor 
 
 
 
-subunit (His-Met-Asn-Gly-Gly-Arg-
Lys-Asn-Glu-Arg-Ala-Leu-Pro-Leu-Pro-Gln-Ser-Ser-Thr-
 
Cys-COOH) as a bait and identified a cDNA encoding 111
amino acids from the mouse embryo cDNA library. The
cDNA product was almost identical to the PDZ domain of
human LARG except for Lys-135 and Ile-166 (Fig. 1, A
and B). LARG had DH and PH domains (Kourlas et al.,
2000) and showed a high degree of sequence similarity to
PDZ-RhoGEF (KIAA0380) except for a proline-rich mo-
tif COOH-terminally adjacent to the DH/PH domain (Fuku-
hara et al., 1999; Rümenapp et al., 1999; Togashi et al.,
2000). Thus, we regarded the cDNA encoding the 111
amino acids as a part of murine LARG. However, we can
not rule out the possibility that the identified fragment by
yeast two-hybrid screening is a LARG-like molecule.
To examine whether LARG interacts directly with the
IGF-1 receptor, we isolated the human LARG cDNA from
the human fetal brain cDNA library and carried out an in
vitro binding assay. Affinity beads coated with glutathione
 
S
 
-transferase (GST) or GST–IGF-1 receptor 
 
 
 
-subunit were
mixed with maltose-binding protein (MBP) or MBP-PDZ
domain of LARG. The bound MBP-PDZ domain of LARG
was then coeluted with the GST fusion proteins by the addi-
tion of glutathione, and the eluted MBP-PDZ domain of
LARG was detected with anti-MBP antibody. MBP-PDZ
domain of LARG was detected in the eluate from GST–
Figure 1. Identification of the IGF-1 receptor-interacting protein. 
(A) Amino acid sequences of the IGF-1 receptor-interacting peptide 
and human LARG. The numbers denote amino acid positions. 
Asterisks denote identical amino acids. The black bars show amino 
acid positions of PDZ domain. (B) Schematic representation of the 
IGF-1 receptor-interacting peptide and human LARG. The numbers 
indicate the amino acid sequence identity in the PDZ domains or 
amino acid numbers. (C) Interaction of MBP-LARG-PDZ domain 
with GST–IGF-1 receptor  -subunit in vitro. MBP, MBP-LARG-PDZ 
domain, or the AF-6–PDZ domain was mixed with GST- or 
GST–IGF-1 receptor-coated beads. The interacting proteins were 
coeluted with GST fusion proteins. The eluates were subjected to 
SDS-PAGE and subjected to immunoblot analysis with anti-MBP 
or anti–AF-6 antibody. The results shown are representative of three 
independent experiments. 
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IGF-1 receptor affinity beads but not in that from the GST
affinity beads (Fig. 1 C). We examined the specificity of the
PDZ domain of LARG by using the PDZ domain of ALL-1
fusion partner from chromosome 6 (AF-6), which is a puta-
tive Ras effector (Van Aelst et al., 1994; Kuriyama et al.,
1996). The PDZ domain of AF-6 was not detected in the
eluate from the GST–IGF-1 receptor affinity beads (Fig. 1
C). Taken together, these results indicate that the PDZ do-
main of LARG binds directly and specifically to the cyto-
plasmic domain of the IGF-1 receptor in vitro.
 
Distribution of LARG
 
To understand the functions of LARG, we produced anti-
LARG antibody against 249 amino acids of the COOH-ter-
minal site and performed immunoblot analysis of several rat
tissues. LARG was expressed in rat adult brain, lung, spleen,
thymus, testis, and ovary but not detectable in heart, kidney,
liver, prostate, small intestine, and colon (Fig. 2 A). Interest-
ingly, LARG was expressed most abundantly in the develop-
ing brains (Fig. 2 A). Moreover, LARG was highly expressed
in various cell lines such as MDCKII, C6 glioma, human
gastric cancer TMK1, and human intestinal cancer HT29
cells (Fig. 2 B). LARG appeared as a doublet in rat tissues
and cells. When we isolated the LARG cDNA from the hu-
man fetal brain cDNA library, we obtained the shorter form
of the LARG cDNA, which lacked the middle region (235–
261 amino acids). The higher band of 
 
 
 
172 kD may be an
intact LARG, judging from the molecular mass of intact
LARG (173,230 D), and the lower band of 
 
 
 
170 kD may
be an alternatively spliced form of LARG.
We next examined the localization of LARG in MDCKII
epithelial cells. The immunoreactivity of LARG was localized
at the lateral membranes and slightly in the cytoplasm (Fig. 2
C). Next, we examined whether LARG is colocalized with the
IGF-1 receptor. Because anti-LARG and anti–IGF-1 receptor
antibodies were rabbit polyclonal ones, we could not perform
double immunofluorescence. Instead, we showed colocaliza-
tion of endogenous IGF-1 receptor and exogenous LARG (he-
magglutinin [HA]-LARG) (Fig. 2 E). The immunoreactivity
of HA-LARG was localized at the lateral membranes and
slightly in the cytoplasm in 94% of the cells, whereas the im-
munoreactivity was localized diffusely in the cytoplasm but
not at the lateral membranes in the remaining 6% of the cells
(Fig. 2, D and E, top). The localization of exogenous HA-
LARG was similar to that of endogenous LARG. Thus, it is
likely that both LARG and the IGF-1 receptor are colocalized
at the lateral membranes. To examine whether LARG is local-
ized at the lateral membranes via its PDZ domain, we exam-
ined the localization of LARG using various mutants. The im-
munoreactivity of HA-LARG-
 
 
 
PDZ was localized diffusely in
the cytoplasm in 60% of the cells (Fig. 2, D and E, bottom),
whereas in the remaining 40% of the cells the immunoreactiv-
ity was still localized partially at the lateral membranes but was
much weaker than that of HA-LARG (Fig. 2, D and E, mid-
Figure 2. Tissue and subcellular distributions of LARG. (A) 
Distribution of LARG in rat tissues. Immunoblot analysis of LARG 
was carried out using anti-LARG antibody. 1, E21 brain; 2, P3 brain; 
3, P6 brain; 4, adult brain; 5, lung; 6, heart; 7, kidney; 8, liver; 9, 
spleen; 10, thymus; 11, testis; 12, ovary; 13, prostate; 14, small 
intestine; 15, colon. The arrowhead denotes the position of LARG. 
(B) Distribution of LARG in cultured cells. Immunoblot analysis of 
LARG was carried out using anti-LARG antibody. 1, C6; 2, MDCKII; 
3, L; 4, NIH 3T3; 5, TMK1; 6, HT29 cells. The arrowhead denotes 
the position of LARG. (C) Subcellular distribution of endogenous 
LARG in MDCKII cells. Confluent MDCKII cells were stained with anti-LARG antibody. (D) Localization of LARG mutants. MDCKII cells were 
transfected with various LARG mutants and then stained with anti-HA antibody. The number of cells used for each calculation are  100, and 
the values shown are average in three independent experiments. (E) Colocalization of exogenous LARG and endogenous IGF-1 receptor. 
MDCKII cells were transfected with pEF-BOS-HA-LARG (top) or pEF-BOS-HA-LARG- PDZ (middle and bottom) and then doubly stained 
with anti-HA and anti–IGF-1 receptor antibodies. The results are representative of three independent experiments. Bars, 10  m. 
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dle). The immunoreactivity of HA-LARG-DH/PH was local-
ized diffusely in the cytoplasm in 81% of the cells, whereas the
immunoreactivity was localized partially at the lateral mem-
branes in the remaining 19% of the cells (Fig. 2 D). The dele-
tion of the RGS domain alone did not affect the localization of
LARG (Fig. 2 D). These results suggest that LARG is translo-
cated to the lateral membranes mainly via its PDZ domain.
Although the RGS domain is not essential, it may play a sec-
ondary role in the translocation of LARG to the lateral mem-
branes, since the deletion of both PDZ and RGS domains
abolished the translocation of LARG to the lateral membranes
more efficiently than that of the PDZ domain alone.
 
Interaction of LARG with the IGF-1 receptor in vivo
 
To determine whether LARG interacts with the IGF-1 re-
ceptor in vivo, we performed coimmunoprecipitation assay.
When the IGF-1 receptor was immunoprecipitated from ly-
sates of MDCKII cells with anti–IGF-1 receptor antibody,
the molecule corresponding to LARG was coimmunoprecip-
itated with the IGF-1 receptor (Fig. 3 A, top). LARG was
not coimmunoprecipitated with control rabbit IgG. The
IGF-1 receptor was also coimmunoprecipitated with LARG
(Fig. 3 A, bottom) when LARG was immunoprecipitated
with anti-LARG antibody. Similar results were obtained
when C6 glioma cells were used instead of MDCKII cells
(unpublished data). These results suggest that LARG inter-
acts and forms a complex with the IGF-1 receptor in vivo.
We next examined the interaction of the recombinant
LARG with the recombinant IGF-1 receptor. Mammalian
expression plasmids harboring Myc-LARG or HA–IGF-1 re-
ceptor 
 
 
 
-subunit were used to cotransfect into L fibroblasts,
since the expression levels of LARG were low and the trans-
fection efficiency was high in L cells. When HA–IGF-1 re-
ceptor 
 
 
 
-subunit was immunoprecipitated with anti-HA an-
tibody, Myc-LARG was coimmunoprecipitated with the
HA–IGF-1 receptor 
 
 
 
-subunit (Fig. 3 B, top). Myc-LARG
was not coimmunoprecipitated with control mouse IgG or
the mock plasmid (HA alone). HA–IGF-1 receptor 
 
 
 
-sub-
unit was also coimmunoprecipitated with Myc-LARG when
anti-Myc antibody was used (Fig. 3 B, bottom). This result
indicates that the recombinant LARG can interact with the
recombinant IGF-1 receptor 
 
 
 
-subunit in L cells.
IGF-1 binds to the IGF-1 receptor and thereby induces
the autophosphorylation of this receptor at its tyrosine resi-
Figure 3. Interaction of LARG with the IGF-1 receptor. (A) Interaction of endogenous LARG with the IGF-1 receptor in vivo. The lysates of 
MDCKII cells were incubated with rabbit IgG, anti-LARG, or the anti–IGF-1 receptor antibody. The immunocomplexes were then precipitated 
and subjected to immunoblot analysis with anti-LARG (top) or anti–IGF-1 receptor antibody (bottom). (B) Interaction of the recombinant 
LARG with the IGF-1 receptor  -subunit. L fibroblasts were cotransfected with pEF-BOS-Myc-LARG and pEF-BOS-HA–IGF-1 receptor 
 -subunit. These lysates were incubated with anti-HA (top) or with the anti-Myc antibody (bottom). The immunocomplexes were subjected 
to immunoblot analysis with anti-Myc (top) or anti-HA antibody (bottom). (C) Effect of IGF-1 on the binding state of LARG and the IGF-1 
receptor. MDCKII cells were serum starved for 48 h and then stimulated with 10 nM IGF-1 for 20 min. The lysates of MDCKII cells were 
incubated with anti–IGF-1 receptor antibody. The immunoprecipitates were subjected to immunoblot analysis with anti-LARG antibody (top), 
anti–IGF-1 receptor antibody (middle), or antiphosphotyrosine antibodies (PY-plus and 4G10) (bottom). (D) Effect of IGF-1 on tyrosine 
phosphorylation of LARG. Under the same condition as C, the lysates of MDCKII cells were incubated with anti-LARG antibody, and then the 
precipitated LARG was subjected to immunoblot analysis with anti-LARG antibody (top) or antiphosphotyrosine antibodies (bottom). The 
results shown are representative of three independent experiments. 
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dues. The phosphorylation of the IGF-1 receptor is thought
to interact with various signaling molecules. We examined
whether the treatment of serum-deprived MDCKII cells
with IGF-1 affected the binding state of LARG and the
IGF-1 receptor. The amounts of LARG that were coimmu-
noprecipitated with the IGF-1 receptor were not changed
under the conditions in which the phosphorylation of IGF-1
receptor was induced (Fig. 3 C). Under the same conditions,
the tyrosine phosphorylated LARG was not detected (Fig. 3
D). Taken together, these results suggest that the interaction
of LARG and the IGF-1 receptor is constitutive and does
not require the phosphorylation of the IGF-1 receptor.
 
GEF activity of LARG for the Rho family GTPases
 
We examined the GEF activity for the Rho family GTPases
in vitro. In this assay, we used a GST fusion protein carry-
ing the DH/PH domain of LARG for monitoring the ex-
change activity toward the Rho family GTPases. The DH/
PH domain of LARG enhanced the dissociation of [
 
3
 
H]-
labeled GDP from RhoA in a time-dependent manner un-
der the conditions where Dbl stimulated the dissociation of
GDP from RhoA (Fig. 4 A). To investigate whether LARG
is a specific GEF for Rho, we further examined the effect of
the DH/PH domain of LARG on other small GTPases,
Rac1, Cdc42, and Ras. The DH/PH domain of LARG
showed an exchange activity for RhoA but not for Rac1,
Cdc42, or Ras (Fig. 4 B). These results indicate that LARG
has the exchange activity for RhoA in vitro but not for
Rac1, Cdc42, or Ras.
It has been reported that the constitutive active form of
RhoA induced the formation of stress fibers in Swiss 3T3
(Ridley and Hall, 1992, 1994) and NIH 3T3 fibroblasts
(Khosravi-Far et al., 1994). Since the expression levels of en-
dogenous LARG and IGF-1 receptor were low in NIH 3T3
cells, we thought that NIH 3T3 cells were appropriate for
evaluating the effects of LARG as a RhoGEF. Serum-
deprived NIH 3T3 cells were transfected with HA-LARG,
and then transfected cells were doubly stained with anti-HA
antibody and TRITC-labeled phalloidin. Overexpression of
LARG induced the formation of stress fibers (Fig. 5, A and
C). The overexpressed LARG was diffusely localized in the
cytoplasm of NIH 3T3 cells but not in the plasma mem-
branes (Fig. 5, A and B). This may be due to the high ex-
pression levels of HA-LARG and/or the low expression lev-
els of the binding partner of LARG such as the IGF-1
receptor in NIH 3T3 cells. The formation of LARG-induced
stress fibers was inhibited by the dominant negative form of
RhoA (Fig. 5, B and D). Overexpression of the DH/PH do-
main of LARG induced the formation of thicker stress fibers
than that induced by LARG (unpublished data). This may
be due to constitutive activation of Rho.
 
Effect of IGF-1 on the Rho signaling pathway
 
We have shown that LARG binds directly to and is colocal-
ized with the IGF-1 receptor. This result led us to examine
whether IGF-1 controls the Rho activity via LARG. It has
been reported that the IGF-1 receptor plays roles when stim-
ulated by IGF-1 in MDCK cells (Sukegawa et al., 1987;
Hauguel-de Mouzon and Kahn, 1991), and we detected the
high expression levels of LARG and the IGF-1 receptor.
Therefore, we thought that MDCKII cells are suitable cells
to monitor the activation of Rho upon the IGF-1 stimula-
tion. To understand the role of IGF-1 in Rho signaling, we
Figure 4. GEF activity of LARG for the Rho family GTPases in 
vitro. (A) The effect of LARG on the dissociation of GDP from RhoA 
in vitro. The DH/PH domain of LARG and Dbl enhanced the 
dissociation of [
3H]-labeled GDP from RhoA in a time-dependent 
manner. (B) The effect of LARG on other small GTPases in vitro. The 
DH/PH domain of LARG showed an exchange activity for RhoA but 
not one for Rac1, Cdc42, or Ras. The results shown are representative 
of three independent experiments.
Figure 5. Effect of LARG on the Rho activity in NIH 3T3 
fibroblasts. Serum-deprived NIH 3T3 cells were transfected with the 
pEF-BOS-HA-LARG (A and C) or -Myc dominant negative form of 
RhoA/-HA-LARG (B and D). The transfected cells were doubly 
stained with anti-HA antibody and TRITC-labeled phalloidin. The 
results shown are representative of three independent experiments. 
Bar, 20  m. 
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examined Rho activity in IGF-1–stimulated MDCKII cells
by a pull-down assay using the GST-Rho–binding domain
of rhotekin (Zondag et al., 2000). However, we could not
detect any increase in GTP-bound Rho in the IGF-1–stimu-
lated cells. The reason for this result may be low expression
levels of endogenous Rho. Therefore, we next performed
a pull-down assay using MDCKII cells stably express-
ing EGFP-RhoA. The expression level of EGFP-RhoA was
more than 10-fold greater than that of endogenous Rho.
MDCKII cells stably expressing EGFP-RhoA were deprived
of serum and then incubated in medium containing 10 nM
IGF-1. The IGF-1–induced Rho activation peaked at
 
 
 
2.5–5 min after stimulation and then returned to basal
levels at 20–30 min (Fig. 6 A).
Next, we used another method in order to examine the ef-
fect of LARG on Rho activity under physiological conditions.
We reported previously that Rho activates Rho-kinase and
thereby Rho-kinase phosphorylates substrates including myo-
sin light chain, ezrin/radixin/moesin family proteins, addu-
cin, and myosin-binding subunit (MBS) of myosin phos-
phatase (Kaibuchi et al., 1999). Using anti-pS854 antibody,
which specifically recognizes the phosphorylated Ser of MBS
at residue 854, we have shown that MBS is phosphorylated
specifically at Ser-854 via the Rho/Rho-kinase pathway dur-
ing the action of HGF in MDCK cells (Kawano et al., 1999).
To examine whether IGF-1 affects the activation of Rho/
Rho-kinase, we measured the amount of MBS phosphory-
lated at Ser-854 in IGF-1–stimulated MDCKII cells. MDCKII
cells were deprived of serum and then incubated in medium
 
containing 10 nM IGF-1. When total cell lysates of nonstim-
ulated MDCKII cells were immunoblotted with anti-pS854
antibody, phosphorylated MBS was detected weakly. The ad-
dition of IGF-1 enhanced the phosphorylation of MBS
within 5–10 min (Fig. 6 B). Similar results were obtained
when the cells were stimulated with HGF (Kawano et al.,
1999). The maximal phosphorylation level of MBS was
 
 
 
5–10-fold over the basal level, and the phosphorylation
level of MBS returned to basal levels at 
 
 
 
60 min (Fig. 6 B).
Furthermore, we examined the effects of Rho-kinase inhibi-
tors, such as Y-32885 and HA1077 (Uehata et al., 1997), on
IGF-1–stimulated phosphorylation of MBS. The IGF-1–
induced phosphorylation of MBS was inhibited by the pre-
treatment of the cells with Y-32885 or HA1077 in a dose-
dependent manner (Fig. 6 C). Similar result was obtained when
the cells were treated with Y-27632, which is also an inhibitor
of Rho-kinase (unpublished data). Taken together, these results
indicate that IGF-1 activates the Rho/Rho-kinase pathway.
 
Roles of LARG in the IGF-1/Rho signaling pathway
 
It has been reported that the RGS domain of PDZ-RhoGEF
(KIAA0380) inhibits stress fibers formation induced by the
heterotrimeric G protein–coupled lysophosphatidic acid
receptor (Rümenapp et al., 1999). The RGS domain is
thought to be a functional interface for interaction with het-
erotrimeric G proteins. Here, we showed that the PDZ do-
main of LARG interacted with the IGF-1 receptor and that
IGF-1 activated the Rho signaling pathway. We speculated
that the PDZ domain of LARG serves as the dominant neg-
ative mutant for the IGF-1–induced Rho/Rho-kinase activa-
tion. We examined whether the PDZ domain of LARG in-
hibits the complex formation of LARG with the IGF-1
receptor. The beads, which were coated with GST–IGF-1
receptor 
 
 
 
-subunit, were mixed with endogenous LARG
from lysates of MDCKII cells and MBP alone, MBP-
LARG-PDZ domain, or AF-6-PDZ domain, and then the
amounts of endogenous LARG bound to GST–IGF-1 re-
ceptor 
 
 
 
-subunit were measured. Endogenous LARG inter-
acted with GST–IGF-1 receptor 
 
 
 
-subunit but not with
GST alone (Fig. 7 A). The amounts of endogenous LARG
bound to GST–IGF-1 receptor 
 
 
 
-subunit were reduced by
the addition of MBP-LARG-PDZ domain but not by the
addition of MBP alone or the PDZ domain of AF-6 (Fig. 7
A). Thus, it is probable that the PDZ domain of LARG can
dissociate endogenous LARG from the IGF-1 receptor and
serve as the dominant negative form.
We examined the effect of the PDZ domain of LARG on
the IGF-1/Rho signaling pathway to determine whether
IGF-1 activates Rho/Rho-kinase via LARG. Serum-deprived
MDCKII cells were transfected with HA alone, HA-LARG-
PDZ domain, HA-LARG-RGS domain, or HA–AF-6–PDZ
domain. The transfected cells were stimulated with IGF-1
for 10 min. In the cells expressing HA-LARG-PDZ and
HA-LARG-RGS domains, the levels of phosphorylated
MBS were lower than that in the cells expressing HA alone
or HA–AF-6–PDZ domain. The expression levels of HA-
LARG-PDZ, HA-LARG-RGS, and HA–AF-6–PDZ do-
mains were almost the same (Fig. 7 B).
It has been reported that IGF-1 affects actin organiza-
tion in mammalian cells (Kadowaki et al., 1986; Lev-
Figure 6. Effect of IGF-1 on the Rho/Rho-kinase signaling pathway. 
(A) Activation of exogenous RhoA by IGF-1. MDCKII cells stably 
expressing EGFP-RhoA were serum starved and then stimulated 
with 10 nM IGF-1 for the indicated minutes. The lysates were 
incubated with GST–Rho-binding domain of rhotekin. The bound 
EGFP-RhoA was subjected to immunoblot analysis with anti-RhoA 
antibody. Arrowheads indicate the positions of GTP-bound 
EGFP-RhoA and total EGFP-RhoA. (B) IGF-induced phosphorylation 
of MBS at Ser-854. Serum-deprived MDCKII cells were stimulated 
with 10 nM IGF-1 for the indicated minutes, and the whole cell 
lysates were resolved by SDS-PAGE followed by immunoblot 
analysis with anti-pS854 (top) or anti-MBS antibody (bottom). 
Arrowheads indicate the positions of the phosphorylated MBS and 
total MBS. (C) Inhibition of the IGF-1–induced MBS phosphorylation 
by Rho-kinase inhibitors. HA1077 (right)- or Y-32885 (left)-pretreated 
serum-deprived MDCKII cells were stimulated with 10 nM IGF-1 for 
10 min, and then the lysates were resolved by SDS-PAGE followed 
by immunoblot analysis with anti-pS854 (top) or anti-MBS antibody 
(bottom). Arrowheads indicate the positions of phosphorylated MBS 
and total MBS. The results shown are representative of three 
independent experiments. 
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enthal et al., 1997). These observations raise the possibil-
ity that the Rho/Rho-kinase pathway participates in the
IGF-1–induced rearrangements of the cytoskeleton. To
examine whether IGF-1 affects actin organization in
MDCKII cells, MDCKII cells were serum starved and
then stimulated with 10 nM IGF-1 for various minutes.
Under the serum-starved conditions, 
 
 
 
10% of the cells
showed thick stress fibers, and the rest of the cells showed
thin and weak stress fibers (Fig. 8 A). The stimulation by
IGF-1 induced thick stress fibers in 
 
 
 
50% of cells within
20–60 min (Fig. 8, A and C). The IGF-1–induced en-
hancement of stress fibers appeared 20–60 min after stim-
ulation and then returned to basal levels later than 
 
 
 
120
min. The PDZ domain of LARG partially inhibited the
IGF-1–induced enhancement of stress fibers, whereas
GST (negative control) or the PDZ domain of AF-6 had
no effects (Fig. 8, B and C). The RGS domain of LARG
partially inhibited the IGF-1–induced enhancement of
stress fibers, though the inhibitory effect was weaker than
that of the PDZ domain of LARG. Taken together, these
results suggest that IGF-1 activates the Rho/Rho-kinase
pathway via LARG.
 
Discussion
 
LARG as an IGF-1 receptor-interacting molecule
 
IGF-1 binds to the IGF-1 receptor and thereby induces the
autophosphorylation of the 
 
 
 
-subunit of this receptor at ty-
rosine residues. The autophosphorylation of the IGF-1 re-
ceptor is thought to initiate a cascade of actions mediating
IGF-1–triggered cellular signal transduction (Myers and
White, 1996). For example, insulin receptor substrate-1
binds to phosphotyrosine residues on the IGF-1 receptor
and thereby initiates IGF-1–mediated cellular signal trans-
duction (White and Kahn, 1994). Here, we showed that
LARG interacted with the nonphosphorylated IGF-1 re-
Figure 7. Effect of the PDZ domain of LARG. (A) Inhibition of the 
complex formation of IGF-1 receptor and LARG by the PDZ domain 
of LARG. Endogenous LARG from MDCKII lysate and MBP, 
MBP-LARG-PDZ domain, or the AF-6–PDZ domain (500 pmol) 
were mixed with GST or GST–IGF-1 receptor-coated beads 
(100 pmol). The bound LARG was subjected to immunoblot 
analysis with anti-LARG antibody. (B) Effect of the PDZ and RGS 
domains of LARG on the IGF-1–induced MBS phosphorylation. 
MDCKII cells were transfected with pEF-BOS-HA, or -LARG-PDZ,
-LARG-RGS, or -AF-6–PDZ domain. These transfected cells were 
serum starved for 48 h and then stimulated or not with 10 nM IGF-1 
for 10 min. The lysates were resolved by SDS-PAGE followed by 
immunoblot analysis with anti-pS854 (top), anti-MBS antibody 
(middle), or anti-HA antibody (bottom). Arrowheads indicate the 
positions of phosphorylated MBS, total MBS, or expressed proteins. 
Asterisks indicate nonspecific bands. The results shown are 
representative of five independent experiments.
Figure 8. Effect of LARG on the IGF-1–induced enhancement of 
stress fibers. (A) IGF-1–induced enhancement of stress fiber formation. 
MDCKII cells were serum starved for 48 h and then stimulated with 
10 nM IGF-1 for the indicated minutes. The stimulated cells were 
stained with TRITC-labeled phalloidin. Arrowheads indicate the 
cells showing IGF-1–induced enhancement of stress fibers. (B and C) 
Effect of the PDZ and RGS domains of LARG on the IGF-1–induced 
enhancement of stress fibers. MDCKII cells were transfected with 
the pEF-BOS-HA-LARG-PDZ domain. The transfected cells were 
serum starved for 48 h and then stimulated with 10 nM IGF-1 for 60 
min. The transfected cells were doubly stained with anti-HA anti-
body and TRITC-labeled phalloidin (B). The cells showing the 
IGF-1–induced enhancement of stress fibers, which were trans-
fected with pEF-BOS-GST, -HA-LARG-PDZ, -HA-LARG-RGS, 
or -HA–AF-6–PDZ, were calculated (C). The number of cells used 
for each calculation is  300, and the values shown are means   SE 
of triplicates. **p   0.01, significance of difference from the cells of 
IGF-1–induced stress fibers analyzed by Student’s t test. 
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ceptor through the PDZ domain. The IGF-1 receptor con-
tains Ser-Thr-Cys, which is not a typical consensus motif
for the PDZ-binding domain, in the COOH-terminal end
(His-Met-Asn-Gly-Gly-Arg-Lys-Asn-Glu-Arg-Ala-Leu-
Pro-Leu-Pro-Gln-Ser-Ser-Thr-Cys-COOH), and this mo-
tif might be responsible for the binding of the IGF-1 recep-
tor to LARG. This also raises the possibility that receptors
other than the IGF-1 receptor can interact with LARG
through its PDZ domain.
It has been reported that RhoGEFs interact with trans-
membrane proteins or receptor-associated proteins. “Trio”
was identified originally as the binding protein of the intracel-
lular domain of leukocyte antigen–related protein, which is a
transmembrane protein tyrosine phosphatase (Debant et al.,
1996). The NH
 
2
 
-terminal GEF domain of Trio has exchange
activity for Rac1 and RhoG, and the COOH-terminal GEF
domain of Trio has exchange activity for RhoA in vitro (De-
bant et al., 1996; Blangy et al., 2000). To our knowledge, the
present results are the first demonstration, indicating the di-
rect binding of RhoGEF to a growth factor receptor.
 
Roles of LARG in the Rho signaling pathway
 
LARG has the PDZ, RGS, DH, and PH domains and shows
a high degree of sequence similarity to PDZ-RhoGEF
(KIAA0380). LARG had the exchange activity for RhoA but
not for Rac1, Cdc42, or Ras. The RGS domain of PDZ-
RhoGEF interacts with activated G
 
 
 
12
 
 or G
 
 
 
13
 
 of heterotri-
meric G proteins, and extracellular signals activate Rho via
this interaction (Fukuhara et al., 1999). A recent report sug-
gests that the RGS domain of LARG interacts with G
 
 
 
12
 
 or
G
 
 
 
13
 
 (Fukuhara et al., 2000). Thus, PDZ-RhoGEF and
LARG may be structurally and functionally similar to each
other. It is possible that PDZ-RhoGEF also interacts with
the IGF-1 receptor, since the PDZ domain of PDZ-RhoGEF
shows a high sequence similarity (75% identical) with that of
LARG (Kourlas et al., 2000). Indeed, our preliminary experi-
ments suggest that recombinant PDZ-RhoGEF interacts
with the IGF-1 receptor in L fibroblasts (unpublished data).
Further studies are required for evaluating the involvement of
PDZ-RhoGEF in the IGF-1 signaling pathway. It has been
reported that PDZ-RhoGEF (KIAA0380) translocates to the
plasma membrane via its proline-rich motif COOH-termi-
nally adjacent to its DH/PH domain and induces cortical ac-
tin reorganization in Swiss 3T3 fibroblasts (Togashi et al.,
2000). The proline-rich motif truncated PDZ-RhoGEF in-
duced the formation of stress fibers but not the cortical actin
reorganization. We showed that LARG, which did not con-
tain a proline-rich motif, induced the formation of stress fi-
bers in NIH 3T3 fibroblasts. Our results together with the
previous observations suggest that LARG is partly different
from PDZ-RhoGEF in terms of the localization site on the
membrane and as a result shows a different phenotype of ac-
tin reorganization.
 
Activating mechanism of LARG in the IGF-1 
signaling pathway
 
In this study, we showed that the IGF-1 receptor forms a
complex with LARG, IGF-1 induced the activation of Rho
and Rho-kinase, and overexpression of the PDZ or RGS do-
main of LARG partially inhibited the IGF-1–induced acti-
vation of Rho-kinase and the enhancement of stress fibers in
a dominant negative fashion. The IGF-1–induced Rho acti-
vation peaked at 
 
 
 
2.5–5 min after stimulation and then re-
turned to basal levels at 20–30 min. The IGF-1–induced
MBS phosphorylation peaked at 
 
 
 
10 min and then re-
turned to basal levels at 
 
 
 
60 min. The IGF-1–induced en-
hancement of stress fibers appeared 20–60 min after stimu-
lation and then returned to basal levels later than 
 
 
 
120 min.
We think that the time courses of IGF-1/Rho/Rho-kinase
signaling pathways are reasonable. These results suggest that
IGF-1 activates the Rho/Rho-kinase pathway via a complex
of the IGF-1 receptor and LARG. As to the molecular
mechanism in which the activation of GEFs can be modu-
lated by extracellular signals, Vav and Vav-2 are thought to
be phosphorylated on tyrosine residues, and then this leads
to activation of the Rho family GTPases (Crespo et al.,
1997; Schuebel et al., 1998). Thus, we speculated that the
phosphorylation of LARG on tyrosine residues might be
necessary for the activation of LARG. We examined whether
IGF-1 induced the tyrosine phosphorylation of LARG in
MDCKII cells and found that the tyrosine phosphorylation
of LARG was not detected under our conditions in which
the IGF-1 receptor was coimmunoprecipitated with LARG
and tyrosine phosphorylated (Fig. 3, C and D). These results
suggest that the interaction of the IGF-1 receptor with
LARG is constitutive and the tyrosine phosphorylation of
LARG is not necessary for its activation. Since Rho/Rho-
kinase is activated by the addition of IGF-1, the phosphory-
lation of the IGF-1 receptor and/or some other unidentified
mechanism may account for the activation of LARG. In this
context, molecules, which interact with the RGS domain
such as heterotrimeric G proteins, may participate in the ac-
tivation of LARG. Alternatively, the binding of IGF-1 to the
IGF-1 receptor may induce the conformational change of
the receptor, leading to the activation of LARG. Further
studies are necessary for understanding the mode of activa-
tion of LARG by IGF-1.
 
Materials and methods
 
Materials and chemicals
 
The cDNA encoding KIAA0382 was provided by Drs. T. Nagase and N.
Nomura (Kazusa DNA Research Institute, Kisarazu, Japan). The plasmid of
GST-rhotekin was provided by Dr. M.A. Schwartz (Scripps Research Insti-
tute, La Jolla, CA). FITC-conjugated anti–rabbit and anti–mouse IgG anti-
bodies and Texas red–conjugated anti–mouse IgG antibody were pur-
chased from Amersham Pharmacia Biotech. TRITC-phalloidin, anti–IGF-1
receptor, and anti-myc (9E10) antibodies were purchased from Sigma-
Aldrich. Anti-HA monoclonal antibody (12CA5) was purchased from
Boehringer. Anti-MBP polyclonal antibody was purchased from New En-
gland Biolabs, Inc. Anti-RhoA antibody was purchased from Cytoskeleton,
Inc. Antiphosphotyrosine antibody (PY-plus) was purchased from Zymed
Laboratories, and 4G10 was purchased from Upstate Biotechnology. Anti-
MBS and anti-pS854 antibodies were generated previously (Kawano et al.,
1999). Rabbit anti-LARG antibody was prepared and purified by use of
GST-LARG (1296–1544 amino acids) as an antigen. Human recombinant
IGF-1 was purchased from GIBCO BRL. HA1077 was provided by Asahi
Chemical Industry. Y-32885 was synthesized as described (Uehata et al.,
1997). All materials used in the nucleic acid study were purchased from
Takara Shuzo Corp.
 
Plasmid constructions
 
The human IGF-1 receptor cDNA was amplified by PCR from the human
fetal liver library. The pLexA- or pBTM116–IGF-1 receptor plasmid, the
fragments of the IGF-1 receptor (1348–1367 amino acids) inserted into
pLexA or pBTM116, were provided by Dr. Hollenberg (Fred Hutchinson 
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Cancer Research Center, Seattle, WA), respectively. The 9.5- and 10.5-d
mouse embryo cDNA-VP16 fusion libraries and pLexA-Lam were also pro-
vided by Dr. Hollenberg (Fred Hutchinson Cancer Research Center). The
pLexA-Lam plasmid expressed human lamin C (66–230 amino acids) as a
fusion product between it and the DNA-binding domain of LexA. For the
mammalian expression plasmid pEF-BOS–HA–IGF-1 receptor 
 
 
 
-subunit or
the 
 
Escherichia coli
 
 expression plasmid pGEX–IGF-1 receptor 
 
 
 
-subunit,
the fragment of the IGF-1 receptor (899–1367 amino acids) was inserted
into pEF-BOS-HA or pGEX-4T-1 (Amersham Pharmacia Biotech), respec-
tively. The human LARG cDNA was amplified by PCR from the human fe-
tal brain MATCHMAKER cDNA library (CLONTECH Laboratories, Inc.)
and then cloned into pGEM-T-Easy (Promega). The fragment of LARG (32–
1544 amino acids), LARG-
 
 
 
PDZ (153–1544 amino acids), LARG- RGS
(the deletion of 262–685 amino acids), LARG-DH/PH (686–1544 amino
acids), LARG-PDZ domain (32–295 amino acids), or LARG-RGS domain
(153–670 amino acids) was cloned into pEF-BOS-Myc or -HA, respec-
tively. The fragment of the LARG-PDZ domain (32–190 amino acids) or
LARG-DH/PH (686–1544 amino acids) was inserted into pMAL-c2 (New
England Biolabs, Inc.) or pGEX-4T-2, respectively.
Yeast strains and media
The genotype of the S. cerevisiae reporter strain used, L40, was MATa trp1
leu2 his3 ade2 LYS2::lexA-HIS3 URA3::lexA-lacZ and that of NA87-11A
was MAT  leu2 his3 trp1 pho3 pho5. Yeast strains were grown at 30 C in
rich medium (1% yeast extract, 2% bacto-peptone, 2% glucose) or in Burk-
folder’s minimal medium with appropriate supplements (Tohe et al., 1973).
Library screening
S. cerevisiae L40, which contained the pLexA–IGF-1 receptor, was trans-
formed with the mouse embryo cDNA library constructed in pVP16. Plas-
mid DNA transformations were performed by the lithium acetate method
(Schiestl and Gietz, 1989). His
  colonies were grown in synthetic medium
at 30 C for 3 d. Approximately 1.8   10
7 transformants were screened,
and then 1,683 colonies were picked up as His
 . Of these colonies, 99
were His
  and LacZ
  as confirmed by replicate plating. The 99 His
  and
LacZ
  clones were cured of pLexA–IGF-1 receptor by growing the cells in
Trp-containing medium and then mating them to yeast strain NA87-11A
that had been transformed with pLexA–IGF-1 receptor or pLexA-Lam.
Mated cells were selected for growth in medium that lacked Trp
(pBTM116) and Leu (pVP16) and were tested for their ability to transacti-
vate HIS3 and a lacZ reporter gene by a  -galactosidase colorimetric filter
assay. 60 diploids transactivated the reporter constructs. Of these 60 dip-
loids, 10 did not transactivate the reporter construct in the presence of the
LexA–lamin fusion protein (Vojtek et al., 1993). The library plasmid was
recovered from the 10 clones and sequenced by an ABI 377 DNA se-
quencer (Perkin-Elmer Applied Biosystems).
In vitro binding assay
GST or MBP fusion proteins were expressed in E. coli BL21(DE3) and purified
according to the manufacturer’s instructions. MBP or MBP-LARG PDZ domain
(600 pmol) was mixed with glutathione–Sepharose 4B beads coated with 100
pmol of either GST or GST–IGF-1 receptor  -subunit in buffer A (20 mM Tris/
HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 5 mM MgCl2). The bound MBP-LARG
PDZ domain was coeluted with GST fusion proteins by the addition of buffer
A containing 10 mM glutathione. Portions of the eluates were subjected to
SDS-PAGE followed by immunoblot analysis with anti-MBP antibody.
Cell culture
NIH 3T3 and MDCKII cells were grown in DME containing 10% calf se-
rum, penicillin, and streptomycin. L cells were grown in DME containing
10% FBS. Although IGF-1 induced the enhancement of actin stress fibers
in parental MDCKII cells, the background of stress fibers was relatively
high. To monitor the enhancement of actin stress fibers, the cell line,
which showed low background of actin stress fibers and high response to
IGF-1, was subcloned and employed for whole studies. The cells showed
the same characteristics as typical MDCK cells, which show characteristics
of polarized epithelial cells. MDCKII cells stably expressing EGFP-RhoA
were grown in DME containing 10% calf serum and 300  g/ml of G418.
Immunofluorescence and laser scanning confocal microscopy
MDCKII cells plated on 13-mm round glass coverslips were fixed in 3.7%
formaldehyde for 10 min and permeabilized with 0.2% Triton X-100 for
10 min. The fixed cells were incubated with primary antibodies for 12 h at
4 C and then were incubated for 1 h with secondary antibodies. The distri-
butions of LARG and the IGF-1 receptor were examined with a laser scan-
ning confocal microscope LSM510 (ZEISS).
Coimmunoprecipitation assay
For coimmunoprecipitation assay of the endogenous proteins, MDCKII
cells were lysed with buffer B (50 mM Tris/HCl, pH 7.5, 1 mM EDTA, 50
mM NaCl, 1 mM DTT, 0.5% [wt/vol] Triton X-100, 10  M p-APMSF, and
10  g/ml leupeptin). The lysate was sonicated and then clarified by centrif-
ugation at 12,000 g for 30 min at 4 C. The soluble supernatant was incu-
bated with anti-LARG antibody, anti–IGF-1 receptor antibody, or rabbit
IgG. For coimmunoprecipitation assay of the recombinant proteins, L cells
were transfected with pEF-BOS-Myc-LARG and pEF-BOS–HA–IGF-1 re-
ceptor  -subunit by lipofectamine (GIBCO BRL) and cultured for 16 h. The
soluble supernatant was incubated with anti-HA or anti-Myc antibody. The
immunocomplexes were then precipitated with protein A–Sepharose (Am-
ersham Pharmacia Biotech) eluted by boiling in sample buffer for SDS-
PAGE, and subjected to immunoblot analyses with the appropriate anti-
bodies.
In vitro GEF assays
Effects of LARG on the dissociation of [
3H]GDP from the Rho family pro-
teins were assayed as described previously (Hoshino et al., 1999). The
[
3H]GDP-bound form of small G proteins was obtained by incubating 10
pmol of each small G protein with 1  M [
3H]GDP (1,000–2,000 cpm/
pmol) for 20 min at 30 C in reaction mixture I (20 mM Tris/HCl, pH 7.5,
10 mM EDTA, 1 mM DTT, 5 mM MgCl2). To prevent the dissociation of
[
3H]GDP from the G proteins, we added MgCl2 to a final concentration of
20 mM and then cooled the mixtures immediately to 4 C. The dissociation
of [
3H]GDP was performed at 25 C by adding a 200-fold excess of unla-
beled GTP and the indicated amounts of GST-DH/PH domain of LARG or
GST-Dbl to reaction mixture II (50 mM Tris/HCl, pH 8.0, 2.9 mM EDTA, 1
mM DTT, 10 mM MgCl2). The diluted mixtures were filtered through nitro-
cellulose filters, and the radioactivity trapped on the filters was counted.
Transfection of NIH 3T3 or MDCKII cells with the expression 
plasmid of LARG
NIH 3T3 cells were transfected with pEF-BOS-HA-LARG or -LARG/-Myc
dominant negative form of RhoA by using lipofectamine and cultured for
24 h. The transfected cells were serum starved for 24 h in DME. MDCKII
cells were transfected with pEF-BOS-GST, or the -HA-LARG-PDZ, -HA-
LARG-RGS, or -HA–AF-6–PDZ domain by using lipofectamine 2000
(GIBCO BRL) and cultured for 24 h. The transfected cells were serum
starved for 48 h in DME and then stimulated with 10 nM IGF-1 for 1 h. The
fixed cells were incubated with primary antibody and then incubated with
secondary antibody and TRITC phalloidin. Fluorescent images were taken
with a laser scanning confocal microscope LSM510.
Pull-down assay (Rho activity assay)
To obtain MDCKII cells stably expressing EGFP-RhoA, MDCKII cells were
transfected with pEGFP-RhoA along with pSVIISR  vector containing the
neomycin resistance gene using lipofectamine 2000, and neomycin-resis-
tant clones were selected. MDCKII cells stably expressing EGFP-RhoA
were incubated for 24 h and then were deprived of serum for 48 h. The
cells were next incubated in DME containing 10 nM IGF-1 at 37 C for var-
ious minutes and then lysed with buffer C (50 mM Tris/HCl, pH 7.5, 100
mM NaCl, 10 mM MgCl2, 1 mM DTT, 1% NP-40, 10  M p-APMSF, 10  g/
ml leupeptin, and 10  g/ml aprotinin). The soluble supernatant was incu-
bated with 2 nmol of GST-rhotekin Rho-binding domain (Zondag et al.,
2000). The bound EGFP-RhoA was eluted by boiling in sample buffer for
SDS-PAGE and subjected to immunoblot analysis with anti-RhoA anti-
body.
Detection of phosphorylated MBS by immunoblot analysis
MDCKII cells were incubated for 24 h, and the cells were deprived of se-
rum for 48 h. For inhibitor assays, serum-deprived cells were treated with
various doses of HA1077 or Y-32885 for 30 min. In the experiments in-
volving the PDZ domain of LARG, serum-deprived cells were transfected
with pEF-BOS-HA, or the -LARG-PDZ, -LARG-RGS, or -AF-6-PDZ domain
by using lipofectamine 2000 and then were cultured. The cells were there-
after incubated in DME containing 10 nM IGF-1 at 37 C for various min-
utes. The IGF-1–stimulated cells were treated with 10% (wt/vol) TCA. The
resulting precipitates were subjected to immunoblotting with anti-MBS or
anti-pS854 antibody.
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